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Aim: To determine the prevalence of clinical and laboratory variables and genetic polymorphisms in
association with diabetic retinopathy (DR) in subjects with type 2 diabetes attending a tertiary referral
diabetes clinic in Durban, South Africa.
Methods: Cross-sectional study on 292 Indian and African patients with type 2 diabetes (71.5% women).
The presence of DR was determined by direct ophthalmoscopy. Clinical and laboratory data were
collected and polymorphisms in the NOS3 (rs61722009, rs2070744, rs1799983) and VEGF (rs35569394,
rs2010963) genes were determined.
Results: DR was present in 113 (39%) subjects. Those with DR were older (60.6  9.6 vs. 55.4  12.9 years,
p ¼ 0.005), had longer duration diabetes (18.5  8.8 vs. 11.9  9.2 years, p < 0.0001), higher HbA1c
(9.2  1.8 vs. 8.8  1.7%, p ¼ 0.049), serum creatinine (106.3  90.2 vs. 75.2  33.4 mmol/l), triglycerides
(2.1  1.2 vs. 1.9  1.6 mmol/l, p ¼ 0.042), proteinuria (72% vs. 28%, p ¼ 0.001), and used more insulin
(78% vs. 39% p ¼ 0.0001), anti-hypertensive (95% vs. 80%, p ¼ 0.0003) and lipid-lowering therapy (70% vs.
56%, p ¼ 0.023). There was no association between DR and any of the NOS3 or VEGF gene polymorphisms
studied, although there were ethnic differences. After adjustment, diabetes duration (OR 1.05, 95% CI 1.01
e1.08), presence of proteinuria (OR 4.15, 95% CI 1.70e10.11) and use of insulin therapy (OR 3.38, 95% CI
1.60e7.12) were associated with DR.
Conclusion: Hyperglycemia, duration of diabetes and proteinuria are associated with DR in Indian and African
patients in South Africa, whereas NOS3 and VEGF gene polymorphisms were not associated with DR.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Diabetic retinopathy (DR) is an important cause of visual loss
and the progressively increasing global prevalence of diabetes
suggests that there will be increasing numbers of persons affected
by this complication. In terms of the global epidemiology of DR, a
recent pooled data analysis, including an excess of 22,000 subjects
from 35 different studies, reported that the age-standardized
prevalence of any DR in subjects aged 20e79 years is 34.6%, pro-
liferative diabetic retinopathy (PDR) 6.96% and diabetic macular
edema (DMO) 6.81% [1]. This analysis did not include any studies
from Africa and data on DR in African populations are sparse [2e4].
A systematic review of diabetes in sub-Saharan Africa between
1999 and 2011 reported that the prevalence of DR varied from 7% to
63% [3]. A previous study of African and Indian subjects with long-27312604774.
NC-ND license. duration diabetes in KwaZulu-Natal, South Africa, showed that of
179 subjects with type 2 diabetes, 64.5% had DR, 47.9% non-
proliferative DR only, 20.8% PDR and 26% had undergone laser
photocoagulation therapy [5]. In this study, the subjects with DR
had higher systolic blood pressure and longer diabetes duration
than those without DR.
The major risk factors for the development of DR include disease
duration, degree of hyperglycemia, hypertension, obesity, dyslipi-
demia and genetic factors [6]. A number of candidate genes have
been shown to be associated with DR, including polymorphisms in
the endothelial nitric oxide synthase (eNOS) gene, the vascular
endothelial growth factor (VEGF) gene, the aldose reductase
(AKR1B1) gene and the angiotensin converting enzyme gene [7].
Furthermore, some studies have shown the intron 4a allele of the
eNOS gene may be associated with a reduced risk of DR [8]. How-
ever, the inﬂuence of risk factors on the development of DR has not
been studied in detail in populations in Africa. The aim of the cur-
rent study was to examine the association between modiﬁable and
non-modiﬁable risk factors and the development of DR in a group of
Table 1
Clinical and laboratory characteristics of Indian and African subjects (n ¼ 292)
Indian African p-value
N ¼ 175 N ¼ 117
Gender
Male 61 (35) 25 (21) 0.02
Female 114 (65) 92 (79)
Age (years) 56.5  12.0 59.2  11.6 0.054
Age at diagnosis (years) 41.5  12.0 45.4  9.5 0.003
Duration diabetes (years) 14.9  10.1 13.8  8.9 0.4
Smoking (%) 29 (16.4) 4 (3.4) 0.002
Insulin therapy (%) 124 (71) 83 (71) 0.9
Anti-hypertensive therapy (%) 149 (85) 108 (92) 0.1
Statin therapy (%) 133 (76) 56 (47.9) <0.0001
Body mass index (kg/m2) 30.0  5.3 35.7  6.5 <0.0001
Systolic BP (mm Hg) 133  15 138  20 0.033
Diastolic BP (mm Hg) 74  10 77  10 0.025
HbA1c (%) [mmol/mol] 9.0  1.7 [75] 9.2  2.0 [77] 0.2
Creatinine (mmol/l) 84  47 92  83 0.4
Microalbuminuria (%) 65 (37) 33 (28.2) 0.2
Proteinuria (%) 21 (12) 11 (9.4) 0.5
Cholesterol (mmol/l) 4.6  1.1 4.3  1.0 0.019
Triglycerides (mmol/l) 2.3  1.8 1.7  0.8 0.0003
HDL cholesterol (mmol/l) 1.2  0.3 1.2  0.3 0.3
LDL cholesterol (mmol/l) 2.4  1.0 2.3  0.9 0.3
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KwaZulu-Natal, South Africa.
Patients and methods
Consecutive patients with type 2 diabetes attending a specialist
referral diabetes clinic at Inkosi Albert Luthuli Central Hospital,
Durban, South Africa, were enrolled. All patients attending the
clinic were enrolled and there were no exclusion criteria. Each
patient underwent clinical assessment including anthropometry
and blood pressure measurement. Direct ophthalmoscopy through
a dilated pupil was conducted by three experienced diabetologists.
In subjects with proliferative DR, conﬁrmation by an ophthalmol-
ogist was obtained. Retinopathy was graded as non-proliferative or
proliferative. Non-proliferative changes included the presence of
microaneurysms, venous beading, hard exudates, cottonwool spots
and intra-retinal hemorrhages. Proliferative changes included
neovascularization, intra-vitreous hemorrhages and ﬁbrous retinal
detachment [9]. Macular edema was not assessed. All patients
provided written informed consent and the study was approved by
the Biomedical Research Ethics Committee of the University of
KwaZulu-Natal. Venous blood was collected for measurement of
creatinine, glycated hemoglobin (HbA1c), lipid levels and for
extraction of genomic DNA. All subjects had spot urine collected for
the measurement of albumin and creatinine excretion and deter-
mination of urine albuminecreatinine ratio (ACR).
Assay methods
Creatinine was measured by the picric acid method, HbA1c by
high performance liquid chromatography, cholesterol by enzymatic
method, using cholesterol esterase and cholesterol oxidase con-
version, followed by Trinder endpoint, triglycerides by the Fossati
three step enzymatic reaction with Trinder endpoint and high
density lipoprotein (HDL) by enzymatic reaction. Low density li-
poprotein (LDL) was calculatedwith the Friedewald equation. Urine
albumin excretion was measured by polyethylene glycol-enhanced
immunoturbidometric assay. Microalbuminuria was deﬁned as ACR
2.5e25 mg/mmol creatinine in males and 3.5e35 mg/mmol
creatinine in females. Proteinuria was deﬁned as persistent dipstix
positivity.
DNA was extracted from peripheral blood leucocytes using an
in-house method involving sucrose lysis, phenol-chloroform
extraction and ethanol precipitation.
Polymerase chain reaction (PCR) and gel electrophoresiswas used
to deﬁne the number of tandem repeat sequences in intron 4
(rs61722009) of the eNOS gene (NOS3). Allelic discrimination with
real-time PCR (Taqman 3100, ABI) was used to determine the prev-
alence of -786 C/T (rs2070744) and 894 G/T (rs1799983) poly-
morphisms in the NOS3 gene and -634 G/C (rs2010963) and -2549
insertion-deletion (rs35569394) polymorphisms in the VEGF gene.
Statistical methods
In bivariate analysis of risk factors associated with retinopathy,
Mann Whitney tests were used for ordinal data, Pearson’s chi
square tests for categorical data and independent t-tests for quan-
titative normal data. Binary logistic regression analysis was used to
determine factors associated with DR after adjustment for con-
founding. Statistical analysis was performed with SPSS version 15.
Results
The total study group included 292 subjects (Indian 175; African
117). Of these, 71.5% (n ¼ 208) were women. The mean age was57.5  12 years, mean duration of diabetes 14.48  9.59 years and
mean HbA1c 9.06  1.83%.
African subjectswere older at diagnosis (45.4 9.5 vs. 41.512.0
years, p ¼ 0.003), had a higher BMI (35.7  6.5 vs. 30.0  5.3 kg/m2,
p < 0.0001), higher SBP (138  20 vs. 133  15 mm Hg, p ¼ 0.033),
higher DBP (77  10 vs. 74  10 mm Hg, p ¼ 0.025), lower total
cholesterol (4.3  1.0 vs. 4.6  1.1 mmol/l, p ¼ 0.019), lower tri-
glycerides (1.70.8 vs. 2.31.8mmol/l, p¼ 0.0003) and fewerwere
treatedwith statins (47.9% vs. 76%,p< 0.0001) (Table 1). Fewer of the
African subjects were current smokers (3.4% vs. 16.4%, p ¼ 0.002).
There was no difference between African and Indian subjects
for age, number on anti-hypertensive therapy, number on insulin
therapy, HbA1c, HDL cholesterol, LDL cholesterol, use of ﬁbrates,
serum creatinine and prevalence of microalbuminuria and
proteinuria.
DR (non-proliferative and proliferative) was present in 113 (39%)
of the subjects. Non-proliferative DR was present in 67 (23%) and
PDR in 46 (15.8%) subjects. There was no difference in the preva-
lence of either non-proliferative or proliferative DR between Afri-
can and Indian subjects (Africans, non-proliferative DR 19.7%, PDR
14.5%; Indians, non-proliferative DR 23.4%, PDR 16.0%, p ¼ 0.996).
Subjects with any DR were compared to those with no DR for
clinical, laboratory and genetic variables. Table 2 shows the clinical
and biochemical variables. Both groups had a similar gender dis-
tribution and ethnic variation. When compared with subjects
without DR, those with DR were older (60.6  9.6 vs. 55.4  12.9
years, p ¼ 0.005) and had longer duration diagnosed diabetes
(18.5  8.8 vs. 11.9  9.2 years, p < 0.0001). A higher proportion
used insulin therapy (78% vs. 39%, p ¼ 0.0001) and anti-
hypertensive therapy (95% vs. 80%, p ¼ 0.0003) and there were
more smokers (58% vs. 42%, p ¼ 0.046).
Subjects with DR had higher HbA1c (9.2  1.8 vs. 8.8  1.7% [77
vs. 73 mmol/mol], p ¼ 0.049) and serum creatinine
(106.3  90.2 mmol/l vs. 75.2  33.4 mmol/l, p < 0.0001). Micro-
albuminuriawas present in fewer subjects with DR (38.5% vs. 61.5%,
p ¼ 0.001) whereas overt proteinuria was present in more subjects
with DR (72% vs. 28%, p ¼ 0.001).
Serum triglyceride levels (2.1  1.2 vs. 1.9  1.6 mmol/l,
p¼ 0.042) were higher in subjects with DR. There was no difference
in total, HDL or LDL cholesterol, although more subjects with DR
were treated with lipid-lowering therapy (70% vs. 56%, p ¼ 0.023).
Table 2
Clinical and laboratory characteristics of subjects with and without diabetic reti-
nopathy (n ¼ 292)
Retinopathy No retinopathy p-value
N ¼ 113 (39%) N ¼ 179 (61%)
Gender
Male 34 50 0.6
Female 79 129
Ethnic group
Indian 72 103 0.2
African 41 76
Age (years) 60.6  9.6 55.4  12.9 0.005
Duration diabetes (years) 18.5  8.8 11.9  9.2 <0.0001
Smoking (%) 58.1 41.9 0.046
Insulin therapy (%) 89 58 0.0001
Anti-hypertensive therapy (%) 96 80 0.0003
Lipid-lowering therapy (%) 70 56 0.023
Body mass index (kg/m2) 31.6  6.4 32.5  6.3 0.2
Systolic BP (mm Hg) 136.7  17.7 134.3  17.03 0.2
Diastolic BP (mm Hg) 72.3  9.5 76.7  10.0 <0.0001
HbA1c (%) [mmol/mol] 9.2  1.8 [77] 8.8  1.7 [73] 0.049
Creatinine (mmol/l) 106.3  90.2 75.2  33.5 <0.0001
Microalbuminuria (%) 38.5 61.5 0.001
Proteinuria (%) 71.9 28.1 0.001
Cholesterol (mmol/l) 4.6  1.2 4.4  0.9 0.1
Triglycerides (mmol/l) 2.1  1.2 1.9  1.6 0.042
HDL cholesterol (mmol/l) 1.1  0.2 1.2  0.3 0.3
LDL cholesterol (mmol/l) 2.3  0.9 2.3  0.7 0.5
Table 3
Prevalence of NOS3 and VEGF gene polymorphisms in subjects with and without







N (%) N (%)
NOS3 gene
rs61722009
aa 17 (10) 8 (7) 0.313
ab 64 (37) 49 (44)
bb 89 (51) 50 (45) 0.215
rs2070744
TT 117 (67) 69 (62) 0.257
TC 51 (29) 39 (35)
CC 6 (4) 3 (3) 0.514
T 285 (82) 176 (80) 0.650
C 63 (18) 44 (20)
rs1799983
GG 137 (79) 81 (73) 0.329
GT 35 (20) 28 (25)
TT 2 (1) 2 (2) 0.952
G 309 (89) 190 (86) 0.317
T 39 (11) 32 (14)
VEGF gene
rs35569394
Deletion 86 (49) 51 (46) 0.651
Insertion/deletion 65 (37) 48 (43)
Insertion 23 (13) 12 (11) 0.675
rs2010963
GG 83 (48) 61 (55) 0.283
CG 79 (45) 42 (38)
CC 12 (7) 8 (7) 0.891
G 245 (70) 164 (74) 0.422
C 103 (30) 58 (26)
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statins (either simvastatin or atorvastatin), of whom 79 (44%)
had DR and 100 (56%) had no DR. Only 6 subjects were treated
with ﬁbrates (1 African and 5 Indian subjects, all treated with
bezaﬁbrate).
When risk factors for DR were stratiﬁed according to ethnicity,
there was no difference between African and Indian subjects.
Genetic datawas available for 288 subjects (117 with DR and 171
with no DR). As shown in Table 3, none of the polymorphisms
studied were associated with the presence of DR. Furthermore
haplotypes of NOS3 were not found to be signiﬁcantly different
between thosewith and thosewithout DR. Although the prevalence
of polymorphisms at each of the ﬁve loci was found to vary between
African and Indian subjects, analysis of NOS3 and VEGF gene poly-
morphisms within each ethnic group separately also failed to show
any association with the presence of DR.
In logistic regression analysis, duration (years) of diagnosed
diabetes (OR 1.05, 95% CI 1.01e1.08, p ¼ 0.006), presence of pro-
teinuria (OR 4.15, 95% CI 1.7e10.1, p ¼ 0.002) and the use of insulin
therapy (OR 3.4, 95% CI 1.6e7.1, p ¼ 0.001) was associated with DR.
There was no association with BMI, blood pressure, lipid levels or
NOS3 or VEGF genotype.
Discussion
The current study has shown that subjects with DR were older,
had longer duration diagnosed diabetes, higher HbA1c, higher
serum creatinine and prevalence of proteinuria, more often treated
with anti-hypertensive therapy and lipid-lowering therapy and
more were smokers. The study failed to show an association with
polymorphisms in NOS3 or VEGF genes.
Meta-analysis of the prevalence and risk factors for DR has
shown that the overall global prevalence of any DR in subjects aged
20e79 years is 34.6% and that of PDR is 6.96% [1]. This report,
however, did not include any studies from Africa. The prevalence of
any DR in the current study (39%) is similar to the global estimate,
although more subjects with PDR were identiﬁed in the current
study (15.8%). Another study in an African population, conducted inMalawi, reported a similar overall prevalence of any DR to the
current study (32.5%) [10]. The prevalence of retinopathy in the
Diabcare Africa Study was lower than that recorded both in the
current study and the Malawian study although the incomplete
ascertainment of data (51% of subjects had an eye examination in
the preceding 12 months), suggests that the prevalence may have
been under-estimated [2].
The ﬁndings in the current study concur with the global meta-
analysis that major risk factors for DR include diabetes duration
and HbA1c. However, although HbA1c was signiﬁcant in bivariate
analysis, it failed to achieve signiﬁcance in multivariate analysis
when controlled for other risk factors. This may be partly accounted
for by the cross-sectional nature of this study. The current study
failed to conﬁrm an association between DR and blood pressure and
this is possibly explained by the higher proportion of those with DR
receiving anti-hypertensive therapy. The measured blood pressures
therefore, reﬂect the efﬁcacy of drug therapy, thereby mitigating
the inﬂuence of recorded blood pressure on DR. In addition,
although data on the speciﬁc type of anti-hypertensive therapy
were not collected, differences in the use of ACE-inhibitors and
other anti-hypertensive agents may also partly account for this
observation.
Although the pathogenesis of DR is multi-factorial, hypergly-
cemia is a major driver of the process, leading to alteration in
capillary permeability and density [11e13]. The current study has
shown a relationship between DR and hyperglycemia in that those
with DR had longer duration of disease, higher HbA1c and more
subjects with DR were treated with insulin than those without DR.
The latter observation is probably a reﬂection of longer diabetes
duration with greater reduction in beta-cell function necessitating
treatment advancement to insulin therapy. This is, however,
speculative, as data on indices of beta-cell function were not
collected.
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with DR [11] and the current study found proteinuria to be more
frequent in subjects with DR, whereas microalbuminuria was more
frequent in those without DR. The association between proteinuria
and DR is substantiated by the ﬁnding of higher serum creatinine in
subjects with DR, suggesting perhaps more renal involvement
(nephropathy). By contrast, some studies have found an association
between microalbuminuria and DR [14]. A recent Chinese study
found microalbuminuria to be associated with an increased risk of
severe or proliferative retinopathy [15]. The reason for a higher
frequency of microalbuminuria in subjects without DR in the cur-
rent study is not known. It is possible that subjects with DR had
longer duration of disease and more often had established ne-
phropathy (shown by a greater frequency of proteinuria), whereas
those without DR and shorter duration of disease, had markers of
incipient nephropathy.
The Hoorn study found a positive relationship between
cholesterol and triglyceride levels and DR in older subjects with
type 2 diabetes [16]. The global meta-analysis also found an asso-
ciation between serum cholesterol and DMO [1]. The current study
failed to show an association between total cholesterol, LDL
cholesterol or HDL cholesterol and DR. However, lipid-lowering
therapy was used more frequently in those with DR. Whether the
efﬁcacy of lipid-lowering therapy altered the relationship between
serum cholesterol and DR is speculative. The ﬁnding that subjects
with DR had higher triglyceride levels than those without DR is
possibly a reﬂection of poorer metabolic control in those with DR.
Several inﬂammatory mediators have been shown to play a role
in the development of DR, including VEGF, nitric oxide, tumor ne-
crosis factor alpha and interleukin-1 beta [17]. The importance of
the role of VEGF in the development of DR is underscored by the
efﬁcacy of anti-VEGF intra-ocular therapy in the management of DR
and particularly in the management of DMO [12,18]. Furthermore,
genetic factors have been shown to have an independent effect on
the development of DR and polymorphisms in a number of candi-
date genes, including VEGF, NOS3 and aldose reductase (AKR1B1)
have been studied [7]. A recent meta-analysis showed that the
rs2010963 (-634 G to C) VEGF polymorphism was associated with
DR in subjects with type 2 diabetes [19]. In a separate study, no
signiﬁcant association was found between the rs25648, rs1570360,
rs3095039, rs35569394 and rs699947 VEGF polymorphisms and DR
[7]. Some studies have shown a relation between NOS3 poly-
morphisms and DR, although meta-analysis has excluded most of
the polymorphisms studied in this gene [7,20]. In agreement with
the generally negative studies of candidate genes in DR, the current
study failed to show a relationship between three NOS3 poly-
morphisms and two VEGF gene polymorphisms and DR. Although
an independent genetic risk for the development of DR may exist,
the effect size is likely to be small and require large study numbers
to demonstrate positive associations.
Strengths of the current study include a multi-ethnic popula-
tion, allowing comparison between groups and the inclusion of
gene polymorphisms in the determination of factors associated
with DR. Limitations include the relatively small numbers of sub-
jects as well as the method of determination of DR; retinal
photography may have improved the diagnostic assessment of DR.In addition the ﬁndings, in this clinic-based study, may not be able
to be extrapolated to the general population in view of the possi-
bility of referral bias.
In conclusion, the current study has shown that in subjects with
type 2 diabetes in KwaZulu-Natal, the well-established risk factors
for DR are afﬁrmed and a number of candidate genes failed to show
an associationwith DR. These ﬁndings suggest that focus on control
of hyperglycemia, blood pressure and serum lipids should remain
the cornerstone of therapy, aiming at preventing the development
of DR and other diabetes complications.References
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